Concepts (119)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mammography | 16 | 2024 | 468 | 1.020 |
Why?
|
| Breast Neoplasms | 21 | 2024 | 3019 | 0.650 |
Why?
|
| Health Literacy | 2 | 2024 | 73 | 0.390 |
Why?
|
| Communication | 2 | 2023 | 462 | 0.320 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 3 | 2017 | 117 | 0.280 |
Why?
|
| Comprehension | 2 | 2024 | 81 | 0.250 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2021 | 477 | 0.210 |
Why?
|
| Patients | 1 | 2023 | 104 | 0.200 |
Why?
|
| Patient Education as Topic | 1 | 2024 | 364 | 0.180 |
Why?
|
| Delayed Diagnosis | 1 | 2020 | 34 | 0.170 |
Why?
|
| Radiology | 2 | 2021 | 204 | 0.170 |
Why?
|
| Neoadjuvant Therapy | 2 | 2021 | 386 | 0.170 |
Why?
|
| Early Detection of Cancer | 1 | 2023 | 418 | 0.160 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2021 | 3486 | 0.160 |
Why?
|
| Image Enhancement | 2 | 2021 | 566 | 0.160 |
Why?
|
| Mastectomy | 2 | 2020 | 252 | 0.160 |
Why?
|
| Contrast Media | 2 | 2021 | 1085 | 0.140 |
Why?
|
| Aromatase Inhibitors | 1 | 2017 | 29 | 0.140 |
Why?
|
| Patient Care Management | 1 | 2017 | 30 | 0.140 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 5 | 2000 | 476 | 0.140 |
Why?
|
| Diagnosis, Computer-Assisted | 2 | 1996 | 332 | 0.140 |
Why?
|
| Radiographic Image Enhancement | 4 | 2000 | 466 | 0.110 |
Why?
|
| Female | 22 | 2024 | 46855 | 0.100 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2002 | 1259 | 0.100 |
Why?
|
| Humans | 27 | 2024 | 90568 | 0.100 |
Why?
|
| Breast | 2 | 2021 | 289 | 0.100 |
Why?
|
| Aged | 9 | 2024 | 19404 | 0.090 |
Why?
|
| Middle Aged | 12 | 2024 | 26327 | 0.090 |
Why?
|
| Surveys and Questionnaires | 3 | 2024 | 2667 | 0.090 |
Why?
|
| Receptors, Estrogen | 1 | 2011 | 395 | 0.080 |
Why?
|
| Breast Diseases | 2 | 2000 | 101 | 0.070 |
Why?
|
| Adult | 9 | 2024 | 26940 | 0.070 |
Why?
|
| Fibroadenoma | 1 | 2005 | 9 | 0.060 |
Why?
|
| Phyllodes Tumor | 1 | 2005 | 7 | 0.060 |
Why?
|
| Carcinoma, Ductal | 1 | 2005 | 18 | 0.060 |
Why?
|
| Spectrum Analysis | 1 | 2005 | 119 | 0.060 |
Why?
|
| Patient Navigation | 1 | 2024 | 15 | 0.060 |
Why?
|
| Patient Portals | 1 | 2024 | 18 | 0.060 |
Why?
|
| BRCA2 Protein | 2 | 2002 | 161 | 0.060 |
Why?
|
| Family Practice | 1 | 2023 | 84 | 0.050 |
Why?
|
| Neoplasms | 1 | 2018 | 3029 | 0.050 |
Why?
|
| Genetic Carrier Screening | 1 | 2002 | 59 | 0.050 |
Why?
|
| Patient Participation | 1 | 2024 | 227 | 0.050 |
Why?
|
| Specialization | 1 | 2002 | 70 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2024 | 791 | 0.050 |
Why?
|
| Electronics | 1 | 2021 | 17 | 0.050 |
Why?
|
| Internet | 1 | 2024 | 324 | 0.050 |
Why?
|
| Qualitative Research | 1 | 2023 | 312 | 0.050 |
Why?
|
| Educational Status | 1 | 2022 | 194 | 0.050 |
Why?
|
| Medicine | 1 | 2002 | 91 | 0.050 |
Why?
|
| Health Personnel | 1 | 2023 | 215 | 0.050 |
Why?
|
| BRCA1 Protein | 1 | 2002 | 205 | 0.050 |
Why?
|
| Electronic Health Records | 1 | 2024 | 355 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2021 | 2893 | 0.040 |
Why?
|
| Patient-Centered Care | 1 | 2022 | 214 | 0.040 |
Why?
|
| Germ-Line Mutation | 1 | 2002 | 349 | 0.040 |
Why?
|
| Medical Oncology | 1 | 2023 | 381 | 0.040 |
Why?
|
| Neoplasm Staging | 3 | 2017 | 2018 | 0.040 |
Why?
|
| Ultrasonography, Mammary | 1 | 1999 | 83 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2021 | 349 | 0.040 |
Why?
|
| Diagnosis, Differential | 5 | 2002 | 1607 | 0.040 |
Why?
|
| Databases, Factual | 2 | 2018 | 875 | 0.040 |
Why?
|
| Biopsy | 2 | 2017 | 1192 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2021 | 8373 | 0.040 |
Why?
|
| ROC Curve | 4 | 2002 | 781 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2002 | 796 | 0.030 |
Why?
|
| Medicare | 1 | 2020 | 429 | 0.030 |
Why?
|
| Mass Screening | 1 | 2000 | 646 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2017 | 377 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2005 | 2523 | 0.030 |
Why?
|
| Prognosis | 2 | 2017 | 3810 | 0.030 |
Why?
|
| Calcinosis | 1 | 1996 | 230 | 0.030 |
Why?
|
| Software | 1 | 2018 | 669 | 0.030 |
Why?
|
| Aged, 80 and over | 3 | 2005 | 6812 | 0.030 |
Why?
|
| Artificial Intelligence | 1 | 1996 | 338 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2021 | 9323 | 0.030 |
Why?
|
| Biopsy, Needle | 2 | 2005 | 233 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2006 | 1806 | 0.020 |
Why?
|
| Sensitivity and Specificity | 3 | 2005 | 2019 | 0.020 |
Why?
|
| Algorithms | 2 | 2002 | 1919 | 0.020 |
Why?
|
| Young Adult | 1 | 2021 | 6425 | 0.020 |
Why?
|
| Prospective Studies | 1 | 1996 | 4345 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 1708 | 0.020 |
Why?
|
| United States | 1 | 2020 | 7142 | 0.020 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2006 | 32 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2006 | 67 | 0.020 |
Why?
|
| Antigens, CD34 | 1 | 2006 | 161 | 0.020 |
Why?
|
| Lasers | 1 | 2005 | 107 | 0.020 |
Why?
|
| Subtraction Technique | 1 | 2005 | 130 | 0.010 |
Why?
|
| Reproducibility of Results | 2 | 2005 | 2782 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2006 | 467 | 0.010 |
Why?
|
| Radiography | 1 | 2006 | 809 | 0.010 |
Why?
|
| Gadolinium DTPA | 1 | 2005 | 256 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 3692 | 0.010 |
Why?
|
| Inflammation | 1 | 2006 | 990 | 0.010 |
Why?
|
| Risk Factors | 2 | 2002 | 5580 | 0.010 |
Why?
|
| Discriminant Analysis | 1 | 2000 | 66 | 0.010 |
Why?
|
| Computers | 1 | 2000 | 111 | 0.010 |
Why?
|
| Physical Examination | 1 | 2000 | 150 | 0.010 |
Why?
|
| Biophysical Phenomena | 1 | 2000 | 124 | 0.010 |
Why?
|
| Biophysics | 1 | 2000 | 153 | 0.010 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2000 | 154 | 0.010 |
Why?
|
| Genes, BRCA1 | 1 | 2000 | 192 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2000 | 591 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2006 | 1550 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2000 | 538 | 0.010 |
Why?
|
| Information Systems | 1 | 1995 | 30 | 0.010 |
Why?
|
| Mathematics | 1 | 1995 | 191 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 1995 | 223 | 0.010 |
Why?
|
| Automation | 1 | 1995 | 112 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 1995 | 360 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2002 | 2364 | 0.010 |
Why?
|
| Artifacts | 1 | 1995 | 246 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 1998 | 1741 | 0.010 |
Why?
|
| Models, Biological | 1 | 2000 | 1770 | 0.010 |
Why?
|
| Adolescent | 1 | 2005 | 9353 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2000 | 1673 | 0.010 |
Why?
|
| Computer Simulation | 1 | 1995 | 1103 | 0.010 |
Why?
|
| Mutation | 1 | 2000 | 4184 | 0.000 |
Why?
|